Metabolic Diseases Archives

Enhancing Treatment of MASH with Combination Therapies

Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...

Overcoming Osteoporosis R&D Bottlenecks

Overcoming Osteoporosis R&D Bottlenecks with Multi-Dimensional OVX Models Against the backdrop of an actively aging global population, osteoporosis has emerged...

Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR

Current weight-loss therapies primarily act on the gut–brain axis, often using incretin-based approaches such as GIP, GLP-1, and glucagon receptor...

Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...

GLP1R and GIPR Dual-Target Drugs in Humanized GIPR Mice

Multi-target drugs targeting GLP1R/GIPR/GCGR have demonstrated superior efficacy for weight loss and glycemic control compared to single-target GLP1R drugs. However,...

Innovative Animal Models for MASH Drug Development

Integrating drug targets, molecular types, and clinical translation Introduction: Metabolic dysfunction-associated steatohepatitis (MASH), a growing global health concern, has garnered...

Integrated Screening and Assay Capabilities Facilitate Peptide Drug Discovery

Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity,...

Combination Therapies in a Mouse MASH Model

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a serious liver disease. If left untreated, MASH can...